Megan L Brophy1,2, Yunzhou Dong1, Huan Tao3, Patricia G Yancey3, Kai Song1, Kun Zhang1,4, Aiyun Wen1, Hao Wu1, Yang Lee1, Marina V Malovichko5, Srinivas D Sithu5, Scott Wong1, Lili Yu1, Olivier Kocher6, Joyce Bischoff1, Sanjay Srivastava5, MacRae F Linton3, Klaus Ley7, Hong Chen1. 1. From the Vascular Biology Program and Department of Surgery, Boston Children's Hospital (M.L.B., Y.D., K.S., K.Z., A.W., H.W., Y.L., S.W., L.Y., J.B., H.C.), Harvard Medical School, MA. 2. Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center (M.L.B.). 3. Atherosclerosis Research Unit, Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (H.T., P.G.Y., M.F.L.). 4. Department of Cardiology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China (K.Z.). 5. Division of Cardiovascular Medicine, Department of Medicine, University of Louisville, KY (M.V.M., S.D.S., S.S.). 6. Department of Pathology and Center for Vascular Biology Research, Beth Israel Medical Deaconess Medical Center (O.K.), Harvard Medical School, MA. 7. Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, CA (K.L.).
Abstract
RATIONALE: Atherosclerosis is, in part, caused by immune and inflammatory cell infiltration into the vascular wall, leading to enhanced inflammation and lipid accumulation in the aortic endothelium. Understanding the molecular mechanisms underlying this disease is critical for the development of new therapies. Our recent studies demonstrate that epsins, a family of ubiquitin-binding endocytic adaptors, are critical regulators of atherogenicity. Given the fundamental contribution lesion macrophages make to fuel atherosclerosis, whether and how myeloid-specific epsins promote atherogenesis is an open and significant question. OBJECTIVE: We will determine the role of myeloid-specific epsins in regulating lesion macrophage function during atherosclerosis. METHODS AND RESULTS: We engineered myeloid cell-specific epsins double knockout mice (LysM-DKO) on an ApoE-/- background. On Western diet, these mice exhibited marked decrease in atherosclerotic lesion formation, diminished immune and inflammatory cell content in aortas, and reduced necrotic core content but increased smooth muscle cell content in aortic root sections. Epsins deficiency hindered foam cell formation and suppressed proinflammatory macrophage phenotype but increased efferocytosis and anti-inflammatory macrophage phenotype in primary macrophages. Mechanistically, we show that epsin loss specifically increased total and surface levels of LRP-1 (LDLR [low-density lipoprotein receptor]-related protein 1), an efferocytosis receptor with antiatherosclerotic properties. We further show that epsin and LRP-1 interact via epsin's ubiquitin-interacting motif domain. ox-LDL (oxidized LDL) treatment increased LRP-1 ubiquitination, subsequent binding to epsin, and its internalization from the cell surface, suggesting that epsins promote the ubiquitin-dependent internalization and downregulation of LRP-1. Crossing ApoE-/-/LysM-DKO mice onto an LRP-1 heterozygous background restored, in part, atherosclerosis, suggesting that epsin-mediated LRP-1 downregulation in macrophages plays a pivotal role in propelling atherogenesis. CONCLUSIONS: Myeloid epsins promote atherogenesis by facilitating proinflammatory macrophage recruitment and inhibiting efferocytosis in part by downregulating LRP-1, implicating that targeting epsins in macrophages may serve as a novel therapeutic strategy to treat atherosclerosis.
RATIONALE: Atherosclerosis is, in part, caused by immune and inflammatory cell infiltration into the vascular wall, leading to enhanced inflammation and lipid accumulation in the aortic endothelium. Understanding the molecular mechanisms underlying this disease is critical for the development of new therapies. Our recent studies demonstrate that epsins, a family of ubiquitin-binding endocytic adaptors, are critical regulators of atherogenicity. Given the fundamental contribution lesion macrophages make to fuel atherosclerosis, whether and how myeloid-specific epsins promote atherogenesis is an open and significant question. OBJECTIVE: We will determine the role of myeloid-specific epsins in regulating lesion macrophage function during atherosclerosis. METHODS AND RESULTS: We engineered myeloid cell-specific epsins double knockout mice (LysM-DKO) on an ApoE-/- background. On Western diet, these mice exhibited marked decrease in atherosclerotic lesion formation, diminished immune and inflammatory cell content in aortas, and reduced necrotic core content but increased smooth muscle cell content in aortic root sections. Epsins deficiency hindered foam cell formation and suppressed proinflammatory macrophage phenotype but increased efferocytosis and anti-inflammatory macrophage phenotype in primary macrophages. Mechanistically, we show that epsin loss specifically increased total and surface levels of LRP-1 (LDLR [low-density lipoprotein receptor]-related protein 1), an efferocytosis receptor with antiatherosclerotic properties. We further show that epsin and LRP-1 interact via epsin's ubiquitin-interacting motif domain. ox-LDL (oxidized LDL) treatment increased LRP-1 ubiquitination, subsequent binding to epsin, and its internalization from the cell surface, suggesting that epsins promote the ubiquitin-dependent internalization and downregulation of LRP-1. Crossing ApoE-/-/LysM-DKO mice onto an LRP-1 heterozygous background restored, in part, atherosclerosis, suggesting that epsin-mediated LRP-1 downregulation in macrophages plays a pivotal role in propelling atherogenesis. CONCLUSIONS: Myeloid epsins promote atherogenesis by facilitating proinflammatory macrophage recruitment and inhibiting efferocytosis in part by downregulating LRP-1, implicating that targeting epsins in macrophages may serve as a novel therapeutic strategy to treat atherosclerosis.
Authors: C Arnoud Meijer; Pum A A Le Haen; Rogier A van Dijk; Mitsuhisa Hira; Jaap F Hamming; J Hajo van Bockel; Jan H Lindeman Journal: Clin Sci (Lond) Date: 2012-05 Impact factor: 6.124
Authors: Xunde Xian; Yinyuan Ding; Marco Dieckmann; Li Zhou; Florian Plattner; Mingxia Liu; John S Parks; Robert E Hammer; Philippe Boucher; Shirling Tsai; Joachim Herz Journal: Elife Date: 2017-11-16 Impact factor: 8.140
Authors: Igor N Zelko; Breandon S Taylor; Trinath P Das; Walter H Watson; Israel D Sithu; Banrida Wahlang; Marina V Malovichko; Matthew C Cave; Sanjay Srivastava Journal: Environ Toxicol Date: 2021-10-30 Impact factor: 4.109
Authors: Yunzhou Dong; Yang Lee; Kui Cui; Ming He; Beibei Wang; Sudarshan Bhattacharjee; Bo Zhu; Tadayuki Yago; Kun Zhang; Lin Deng; Kunfu Ouyang; Aiyun Wen; Douglas B Cowan; Kai Song; Lili Yu; Megan L Brophy; Xiaolei Liu; Jill Wylie-Sears; Hao Wu; Scott Wong; Guanglin Cui; Yusuke Kawashima; Hiroyuki Matsumoto; Yoshio Kodera; Richard J H Wojcikiewicz; Sanjay Srivastava; Joyce Bischoff; Da-Zhi Wang; Klaus Ley; Hong Chen Journal: Nat Commun Date: 2020-08-07 Impact factor: 14.919